The ORION-16 trial demonstrates that inclisiran, a twice-yearly siRNA therapy, significantly and safely reduces LDL cholesterol in adolescents with heterozygous familial hypercholesterolaemia, offering a promising solution for long-term adherence and cardiovascular risk reduction in this high-risk pediatric population.